Rights issue in Oasmia Pharmaceutical (SE) — SEK 123 million

Carnegie acted as adviser to Oasmia in the rights issue of SEK 123 million. Oasmia develops novel formulations of already established cytostatics for both human and veterinary use, which in comparison to current alternatives show improved performance, a reduced side-effect profile and an expanded therapeutic area. The portfolio comprises five product candidates, of which two are in registration phase.November 2012.